StockData
UroGen Pharma Ltd. logo

UroGen Pharma Ltd. (URGN) stock

URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$29.87+1.77 (+6.30%)

Close on Nov 17, 2026Market cap $1.46BP/E –Yield –

UroGen Pharma EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

UroGen Pharma's EV/EBITDA was 92.1× on Jan 31, 2018.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2018Jan 31, 201892.1×+27.5
2017Dec 29, 201764.6×–

More UroGen Pharma figures

See a number that looks wrong?